Respiratory Syncytial Virus (RSV) Hospitalizations of US Preterm Infants Born at 29-35 Weeks Gestational Age: Proportions by Chronologic Age and Birth Month
Background: Respiratory syncytial virus hospitalizations (RSVH) in preterm infants 2935 weeks gestational age (wGA) are often severe, frequently resulting in intensive care unit admission and the need for invasive mechanical ventilation. Assessing both chronologic age and birth month (a marker of RSV-seasonal exposure) may provide a practical approach to stratifying RSVH risk in otherwise healthy preterm infants 2935 wGA. The objective of this study was to evaluate the comparative distributions of community-acquired RSVH by chronologic age and birth month among infants 2935 wGA not receiving immunoprophylaxis.
Methods: The SENTINEL1 study (NCT02273882) was conducted at 46 US sites over 2 RSV seasons (1 Oct30 Apr) in 20142015 and 20152016. At each site, all infants 2935 wGA with community-acquired, laboratory-confirmed RSV were included if aged <12 mo, hospitalized for ≥24 h with RSV, and had not received RSV immunoprophylaxis. Information on RSVH by chronologic age, gestational age, and birth month was systematically collected on all eligible infants.
Results: 1378 infants 2935 wGA were identified over 2 RSV seasons. Case distribution by chronologic age and gestational age is presented in Figure 1, and distribution by birth month and gestational age is presented in Figure 2. Among infants 2932 wGA, 55% of RSVH occurred among those <4 mo chronologic age. Among infants 3334 wGA and 35 wGA, 55% of RSVH occurred among those <3 mo chronologic age. Among infants 2932 wGA, 67% of RSVH occurred among infants born Aug-Jan. Among infants 3334 wGA and 35 wGA, 66% and 65% of RSVH, respectively, occurred in infants born Sep-Jan.
Conclusion: RSVH remains an important problem among preterm infants 2935 wGA. Incorporating chronologic age and birth month can enhance risk stratification around prevention and improve anticipatory guidance to families of preterm infants.
Study supported by AstraZeneca.
E. J. Anderson,
NovaVax: Research Contractor , Research support
Regeneron: Research Contractor , Research grant
MedImmune: Research Contractor , Research grant and Research support
M. L. Forbes, AstraZeneca/MedImmune: Investigator and Speaker's Bureau , Research support and Speaker honorarium
P. A. Checchia, AstraZeneca/MedImmune: Investigator , Research support
J. B. Domachowske II, AstraZeneca/MedImmune: Investigator , Research support
L. R. Krilov, AstraZeneca/MedImmune: Consultant , Research grant and Research support
N. B. Halasa, Sanofi Pasteur: Research Contractor , Research support
Astra Zeneca: Research Contractor , Grant recipient
J. P. Devincenzo, AstraZeneca/MedImmune: Investigator , Research support
C. Rizzo, AstraZeneca: Employee , Salary
K. K. McLaurin, AstraZeneca: Employee , Salary
C. S. Ambrose, AstraZeneca: Employee , Salary